Is Geron Corporation (GERN) overvalued? · rev $237.0K
Geron Corporation (GERN) is a biotechnology company listed on US.
This page asks whether Geron Corporation (GERN) looks expensive on cached numbers — not a short thesis.
Latest reported GERN revenue for 2023-12-31 was $237.0K. Net income was -$184.1M. Revenue was down 60.2% from 2022-12-31 to 2023-12-31. GERN currently screens at market cap $878.9M.
GERN currently screens at market cap $878.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GERN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GERN stock page for the full model, not this heading.
Not investment advice.